Camzyos (mavacamten) / BMS - LARVOL DELTA

Artificial Intelligence-Based Electrocardiographic Analysis Facilitated Diagnosis of Hypertrophic Cardiomyopathy With Successful Treatment Using Mavacamten. (PubMed, JACC Case Rep) - "The case describes the use of AI-ECG to diagnose HCM appropriately in a 61-year-old symptomatic patient with no previous knowledge of the disease. Following an appropriate diagnosis of HCM, the patient was initiated on the novel cardiac myosin inhibitor mavacamten, with an excellent clinical response."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Efficacy of Mavacamten in Reducing Cardiac Obstruction in an Elderly Patient with Hypertrophic Cardiomyopathy: A Case Study. (PubMed, Am J Case Rep) - "This may have contributed to significant symptom relief and an improved quality of life. Further research is needed to better understand how genotype and phenotype influence treatment response, which could help refine our approach to optimizing non-invasive medical therapies."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Echocardiographic evolution of symptomatic patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: experience of a portuguese terciary care center (HEART FAILURE 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Early detection of treatment response to mavacamten in hypertrophic obstructive cardiomyopathy with severe mitral regurgitation using magnetocardiography (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Treatment of obstructive hypertrophic cardiomyopathy with mavacamten (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Decrease of ECG hypertrophy indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Long-term efficacy of mavacamten on cardiac structure and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial (HEART FAILURE 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial (HEART FAILURE 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Evaluation of cardiac MRI parameters during mavacamten treatment in obstructive hypertrophic cardiomyopathy: three- and six-month results (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten eligibility in an Irish hypertrophic cardiomyopathy cohort (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Real-world insights into mavacamten use for obstructive hypertrophic cardiomyopathy: symptomatic improvement before gradient reduction? (HEART FAILURE 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Assessment of changes in right-sided cardiac echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Change of 3D echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Early experience with mavacamten in a tertiary care center (HEART FAILURE 2025) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Long-term efficacy and safety of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial (HEART FAILURE 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Changes in global myocardial work indices during mavacamten treatment in obstructive hypertrophic cardiomyopathy (HEART FAILURE 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten use in a real-world cohort of obstructive hypertrophic cardiomyopathy patients: insights from the initial centre experience (HEART FAILURE 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Real-world effectiveness of MAVacamtEN in Canada: insights from the MAVEN study (HEART FAILURE 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

How early can we identify differences in regional myocardial deformation after mavacamten initiation for hypertrophic obstructive cardiomyopathy: a pilot study (HEART FAILURE 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. (PubMed, Open Heart) - "Mavacamten treatment was associated with significant symptomatic improvement, reduced LVOT gradients and improved biomarker profiles in patients with oHCM. The implementation of clinical services to deliver mavacamten in the UK should not follow a 'one-size-fits-all' approach but rather leverage the unique strengths of each specific centre."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • CYP2C19

U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications (Businesswire) - "Bristol Myers Squibb...announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules)....FDA-approved updates include reduced frequency of required echo monitoring from once every 12 weeks to every 6 months for patients with left ventricular ejection fraction (LVEF) ≥55% and a Valsalva left ventricular outflow tract (LVOT) gradient <30 mmHg (or Valsalva LVOT ≥30 mmHg without up-titration) who have reached the maintenance phase (at Week 12 or later). Additionally, CAMZYOS is no longer contraindicated with moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors, which were adjusted to drug interactions....Updated U.S. label is supported by data including long-term clinical and real-world evidence which reinforce the strong safety profile of CAMZYOS."

FDA event • Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial (Businesswire) - P3 | N=420 | ODYSSEY-HCM (NCT05582395) | Sponsor: Bristol-Myers Squibb | "Bristol Myers Squibb...today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM) did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO2). No new safety signals were observed....Importantly, these results do not change the favorable benefit-risk profile that has been consistently demonstrated across our Camzyos clinical trials in obstructive HCM and the robust body of real-world effectiveness and safety evidence showing its benefit for people living with obstructive HCM around the world."

P3 data • Non-obstructive Hypertrophic Cardiomyopathy

Assessment of Positive Cardiac Remodeling in Hypertrophic Obstructive Cardiomyopathy Using an Artificial Intelligence-Based Electrocardiographic Platform in Patients Treated With Mavacamten. (PubMed, Mayo Clin Proc Digit Health) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy